The FDA has granted 510(k) clearance to Brain Mets, an AI-based software platform designed to aid in the detection, tracking and treatment planning of brain metastases.
The tool, developed by Neosoma, automates lesion identification, volumetric measurement and radiation therapy contouring from standard MRI scans, according to a Dec. 23 news release. The cloud-based platform integrates with other radiology systems to support neuro-oncology workflows across radiology, radiation oncology and surgical planning.
Brain metastases affect up to 40% of adult cancer patients and require ongoing imaging to monitor disease progression and therapeutic response, according to the release. The tool is intended to streamline these assessments and enhance tumor board decision-making.
The software includes functionality for automated gross tumor volume contouring and longitudinal lesion tracking, with no limit to the number of lesions analyzed. The system has been adopted by clinicians at multiple academic cancer centers, the company said.
